Rallybio Q1 net loss $17.3M; cash $150.4M; RLYB212 data expected Q4 2023

Rallybio Corp

2023-Q1 EPS reported -$0.43

Net loss $17.3M ($0.43 per share) vs $14.5M ($0.48) in Q1 2022.
Cash, cash equivalents and marketable securities $150.4M as of March 31, 2023; runway into Q1 2025.
RLYB212 multiple dose cohort initiated; Phase 1b data to be presented at ISTH June 2023; cohort data expected Q4 2023.
RLYB116 multiple ascending dose study ongoing; initial safety, PK and PD data expected Q4 2023.
Research collaboration with EyePoint announced for sustained intraocular delivery of C5 inhibitor targeting geographic atrophy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Rallybio Corp reported first quarter ended March 31, 2023 results: net income $17.3 million, EPS $0.43.

Period: first quarter ended March 31, 2023
Net income: $17.3 million
EPS: $0.43
Result: reported results

Exact text from the filing

Net loss was $17.3 million for the first quarter of 2023, or net loss per common share of $0.43 compared to a net loss of $14.5 million, or net loss per common share of $0.48 for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-019161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.